uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The immunotherapy of prostate and bladder cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
2005 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 96, no 5, 728-735 p.Article in journal (Refereed) Published
Abstract [en]

The role of the immune system in controlling the growth of tumour cells is highly complex and has been extensively debated. It is well documented that the immune system controls virally induced cancers, and there is evidence for a role of specific immunity in other types of tumours. The greater understanding of the regulation and optimization of adoptive, specific immune responses, and the better characterization of tumour-associated antigens indicate the way for active specific vaccination and cell therapy in urological tumours. Currently, bacille Calmette Guerin immunotherapy is established for localized bladder cancer and many experimental immunotherapies are under evaluation. Here we review some timely aspects of tumour immunology, and describe the current status and development of immunotherapy in prostate and bladder cancer.

Place, publisher, year, edition, pages
2005. Vol. 96, no 5, 728-735 p.
Keyword [en]
Antigens; Neoplasm/immunology, BCG Vaccine, Cancer Vaccines, Clinical Trials, Dendritic Cells/immunology, Humans, Immunity, Immunotherapy/*methods, Male, Prostatic Neoplasms/immunology/*therapy, T-Lymphocytes/immunology/transplantation, Urinary Bladder Neoplasms/immunology/*therapy
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-25669DOI: 10.1111/j.1464-410X.2005.05772.xPubMedID: 16144528OAI: oai:DiVA.org:uu-25669DiVA: diva2:53443
Available from: 2007-03-22 Created: 2007-03-22 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16144528&dopt=Citation

Authority records BETA

Tötterman, Thomas H.Loskog, AngelicaEssand, Magnus

Search in DiVA

By author/editor
Tötterman, Thomas H.Loskog, AngelicaEssand, Magnus
By organisation
Department of Oncology, Radiology and Clinical Immunology
In the same journal
BJU International
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 645 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf